PIE II: Pharmacological Intervention in the Elderly II - Full Text View

Sponsor:	Wake Forest University
Collaborator:	National Institute on Aging (NIA)
Information provided by (Responsible Party):	Dalane W. Kitzman, Wake Forest University
ClinicalTrials.gov Identifier:	NCT00123955

Purpose

The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).

Condition	Intervention	Phase
Diastolic Heart Failure Heart Failure, Congestive	Drug: Spironolactone Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Exercise Intolerance in Elderly Diastolic Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure

Drug Information available for: Spironolactone

U.S. FDA Resources

Further study details as provided by Wake Forest University:

Primary Outcome Measures:

Exercise intolerance [ Time Frame: Baseline, 4 and 9 months ] [ Designated as safety issue: No ]
quality of life [ Time Frame: Baseline, 4 and 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Concentric left ventricular remodeling [ Time Frame: Baseline, 4 and 9 months ] [ Designated as safety issue: No ]
left ventricular diastolic stiffness [ Time Frame: Baseline, 4 and 9 months ] [ Designated as safety issue: No ]

Enrollment:	80
Study Start Date:	April 2005
Study Completion Date:	June 2009
Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Spironolactone	Drug: Spironolactone 25mg tablet daily for 9 months Other Name: Aldactone
Placebo Comparator: 2 Placebo	Drug: Placebo Placebo tablet daily for 9 months

Detailed Description:

Exercise intolerance due to HFPEF is a major cause of disability among older Americans. Several lines of evidence suggest that aldosterone antagonism may improve exercise tolerance in HFPEF. Therefore, the primary aim of this study is to test the hypothesis that spironolactone will improve exercise tolerance and quality of life in elderly patients with isolated HFPEF. A total of 72 participants aged 60 or older will be randomized to receive either spironolactone 25mg daily or a placebo.

Eligibility

Ages Eligible for Study:	60 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ambulatory
Medically stable
Ages 60 or older
Diagnosis of diastolic heart failure

Exclusion Criteria:

Valvular heart disease
Significant change in cardiac medication within the past 4 weeks
Uncontrolled hypertension
Recent or debilitating stroke
Cancer or other noncardiovascular conditions with life expectancy less than 2 years
Anemia
Elevated serum potassium
Renal insufficiency
Psychiatric disease (uncontrolled major psychoses, depression, dementia, or personality disorder)
Allergy to spironolactone; currently taking spironolactone or any aldosterone antagonist
Plans to leave area within 1 year
Refuses informed consent
Failure to pass screening tests: pulmonary function, echocardiogram, or exercise
Contra-indications to magnetic resonance imaging [MRI] (indwelling metal-containing prosthesis; pacemaker or defibrillator; history of welding occupation; uncontrollable claustrophobia)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00123955

Locations

United States, North Carolina
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157

Sponsors and Collaborators

Wake Forest University

National Institute on Aging (NIA)

Investigators

Principal Investigator:

Dalane W. Kitzman, MD

Professor of Internal Medicine, Cardiology, Director of Echocardiography, Wake Forest University Health Sciences

More Information

Publications:

Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002 Nov 6;288(17):2144-50.

Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991 Apr;17(5):1065-72.

Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001 Feb 15;87(4):413-9.

Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102(22):2700-6. Erratum in: Circulation 2001 Jan 23;103(3):476.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.

Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, Caruso B, Zardini P. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Feb 15;89(4):403-7.

Responsible Party:	Dalane W. Kitzman, Professor Internal Medicine Cardiology/Gerontology, Wake Forest University
ClinicalTrials.gov Identifier:	NCT00123955 History of Changes
Other Study ID Numbers:	AG0030, R01AG018915, 2R01 AG018915-05
Study First Received:	July 22, 2005
Last Updated:	December 21, 2011
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Heart Failure
Heart Failure, Diastolic
Heart Diseases
Cardiovascular Diseases
Spironolactone
Aldosterone Antagonists
Hormone Antagonists

Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Diuretics
Natriuretic Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012